Revance Therapeutics (RVNC) Tops Q3 EPS by 25c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.64), $0.25 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
• KB Home (KBH) PT Lowered to $50 at RBC Capital